Prolactin bioassay and hyperprolactinemia.
The Nb2 rat lymphoma bioassay (BA) for prolactin (PRL) was performed in 26 subjects with hyperprolactinemia, 17 of whom had radiologic evidence of a pituitary adenoma. All subjects were treated with the long acting dopamine agonist CV 205-502. The radioimmunoassay (RIA) PRL significantly decreased with treatment but the BA/RIA PRL remained essentially the same, indicating that the relative bioactivity was unaffected.
Department of Psychiatry, University of Texas Medical School, Houston.
C A
CA
Peabody
P N
PN
Schultz
M D
MD
Warner
I G
IG
Worsley
H G
HG
Friesen
N A
NA
Samaan
D000236:Adenoma / Q000150:complications; D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000209:etiology; D000634:Aminoquinolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001681:Biological Assay; D015259:Dopamine Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D005687:Galactorrhea / Q000209:etiology; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms; D011388:Prolactin / Q000097:blood*; D011863:Radioimmunoassay
D000634:Aminoquinolines; D015259:Dopamine Agents; C046650:quinagolide; D011388:Prolactin; D013006:Growth Hormone